ArticleCancers2026
Head-to-Head Comparison of [68Ga]Ga-PSMA-11 PET Interpreted with Non-Contrast CT Versus Excretory-Phase CT Urography in Biochemical Recurrence of Prostate Cancer.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to determine whether incorporating radiologic contrast during the excretory (urographic) phase enhances the detection of recurrence on [68Ga]Ga-PSMA-11 PET/CT in patients with biochemical relapse (BCR) following radical prostatectomy (RP).
methodsA single-center retrospective analysis included 43 men with BCR after RP who underwent [68Ga]Ga-PSMA-11 PET/CT. Each patient underwent two comparative assessments. In the first assessment, whole-body PET images acquired at 60 min post-injection were fused with the non-contrast CT from early dynamic pelvic imaging (PET/CTd), and local recurrence and pelvic nodal involvement were evaluated according to PROMISE V2 and E-PSMA frameworks by two blinded readers. In the second assessment, the same PET dataset was fused with the excretory-phase CT urography (CT-U) obtained during the same imaging session at 60 min post-injection, and the same parameters were re-evaluated. Endpoints included surgical-bed classification, peri-ureteric nodal status, reader confidence, ureter visualization/opacification, and interpretation time. Inter- and intra-observer agreement was assessed, and discrepancies were resolved by consensus.
resultsSurgical-bed positivity decreased from 12/43 (27.9%) on PET/CTd to 5/43 (11.6%) on PET/CT-U, leading to reclassification in seven patients (
conclusionsAdding an excretory-phase CT urography to [68Ga]Ga-PSMA-11 PET/CT improves diagnostic confidence, reduces interpretive uncertainty in the surgical bed, clarifies peri-ureteric nodal findings, enhances ureter visualization, and shortens interpretation time. CT-U is a practical enhancement to low-dose PET/CT protocols for BCR after RP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.